In a sector of constant innovation, a company must be something special if even the experts are excited. These are the four ...

In my opinion, these results, which are presented in the chart below ... NDA submission for lenacapavir, a first-in-class capsid inhibitor of HIV-1. If approved, it would be the first twice ...

If you've been prescribed buspirone, it's important to know certain interactions that can affect the safety or effectiveness of your buspirone or other drugs. The chart ... are a class of drugs ...

When it comes to antibiotic stewardship and clinical care, Brad Spellberg, MD, just wants to see the data.

Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. Researchers ...

In cell lines, the HIV/AIDS drug efavirenz inhibited the replication by almost 99% even at low micromolar concentrations. In the case of mice, the efavirenz treatment “significantly” reduced ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

It has been in use for more than a decade as an HIV treatment by millions of adults and adolescents living with HIV in over 100 countries. But there’s no specific drug formulation for newborns.

He said people as young as 13 were contracting HIV through intravenous drug use. Health authorities also warn the alarming practice of "bluetoothing" is exacerbating the problem. It involves ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

A groundbreaking injectable that would curb the spread of HIV is at risk due to Donald Trump's funding cuts on foreign aid. A groundbreaking injectable designed to curb the global spread of HIV is ...